The Alliance for Safe Biologic Medicines (ASBM) says FDA should use “meaningful” four letter suffixes in naming biologics and biosimilars, rather than using suffixes “devoid of meaning” that the agency proposed as a naming scheme in a draft guidance and proposed rule released last week. FDA said in the proposals that it was open to the idea of using meaningful suffixes. ASBM, whose membership includes the biologic trade lobby, patient and physician groups, says meaningful suffixes limit the proliferation of...